Anticipated shortage
Anticipated shortage due to expanded PBS indications for heart failure and CKD driving increased demand beyond forecast.
Expected resolution: 30 September 2025
empagliflozin
Jardiance
25 mg · tablet · Chronic Kidney Disease
PBS Pricing
| General patient co-payment | $31.60 |
| Concession co-payment | $7.70 |
| Full dispensed price | $78.40 |
PBS Information
- Item code
- REN006
- Drug name
- empagliflozin
- Brand name
- Jardiance
- Manufacturer
- Boehringer Ingelheim
- Formulation
- tablet
- Strength
- 25 mg
- Max quantity
- 30 units
- Max repeats
- 5
- PBS listed
- Yes
- Therapeutic group
- Chronic Kidney Disease
TGA Reference: TGA-MSI-2025-024 · Sponsor: Boehringer Ingelheim Pty Ltd
MedWatch is for informational purposes only and does not constitute medical advice. Never stop or change your medicines without consulting your doctor or pharmacist. In an emergency, call 000. Medication queries: National Medicines Line 1300 633 424.